ReviewDrug design, development and therapy2022
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Review in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.International journal of clinical oncology · 2025Trial
- Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management.Journal of clinical medicine · 2026Review
- Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.Future oncology (London, England) · 2026Article
- Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.Future oncology (London, England) · 2026Observational
- The double-edged sword of tumor-targeted treatment: the influence of targeted therapy on the heart.Translational cancer research · 2026Review
- Article
- Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Longitudinal changes in left atrial function during chronic ibrutinib therapy: a prospective observational study.Frontiers in cardiovascular medicine · 2026Article
- Chronic lymphocytic leukemia: criteria for first-line therapeutic choice-an opinion paper.Medical oncology (Northwood, London, England) · 2025Review
- Article
- Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting.Current oncology (Toronto, Ont.) · 2025Article
- Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin.Cancer innovation · 2025Article
- Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study.Frontiers in oncology · 2025Article
- Beyond Atrial Fibrillation and Heart Failure: Ibrutinib-induced Pericardial Effusion.Journal of community hospital internal medicine perspectives · 2025Article
- A review of TEC family kinases and their inhibitors in the treatment of alopecia areata.Archives of dermatological research · 2024Review
- Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib.International journal of molecular sciences · 2024Article
- A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF ScoreTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.EClinicalMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotoxicity remain unclear. In this review, we discuss the pharmacological properties of ibrutinib, the incidence and mechanisms of ibrutinib-induced cardiotoxicity, and practical management to prevent and treat this condition. We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.